Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 69

1.

The genomic landscape of metastatic castration-resistant prostate cancers reveals multiple distinct genotypes with potential clinical impact.

van Dessel LF, van Riet J, Smits M, Zhu Y, Hamberg P, van der Heijden MS, Bergman AM, van Oort IM, de Wit R, Voest EE, Steeghs N, Yamaguchi TN, Livingstone J, Boutros PC, Martens JWM, Sleijfer S, Cuppen E, Zwart W, van de Werken HJG, Mehra N, Lolkema MP.

Nat Commun. 2019 Nov 20;10(1):5251. doi: 10.1038/s41467-019-13084-7.

2.

Variation in the Prescription of Androgen Deprivation Therapy in Intermediate- and High-risk Prostate Cancer Patients Treated with Radiotherapy in the Netherlands, and Adherence to European Association of Urology Guidelines: A Population-based Study.

Rijksen BLT, Pos FJ, Hulshof MCCM, Vernooij RWM, Jansen H, van Andel G, Wijsman BP, Somford DM, Busstra MB, van Moorselaar RJA, Kaa CAH, van Leenders GJLH, Hamberg P, van den Berkmortel F, Fütterer JJ, Kiemeney LA, van Oort IM, Aben KKH.

Eur Urol Focus. 2019 Nov 17. pii: S2405-4569(19)30346-3. doi: 10.1016/j.euf.2019.11.005. [Epub ahead of print]

PMID:
31748122
3.

Blood-derived dendritic cell vaccinations induce immune responses that correlate with clinical outcome in patients with chemo-naive castration-resistant prostate cancer.

Westdorp H, Creemers JHA, van Oort IM, Schreibelt G, Gorris MAJ, Mehra N, Simons M, de Goede AL, van Rossum MM, Croockewit AJ, Figdor CG, Witjes JA, Aarntzen EHJG, Mus RDM, Brüning M, Petry K, Gotthardt M, Barentsz JO, de Vries IJM, Gerritsen WR.

J Immunother Cancer. 2019 Nov 14;7(1):302. doi: 10.1186/s40425-019-0787-6.

4.

Real-world Outcomes of Sequential Androgen-receptor Targeting Therapies with or Without Interposed Life-prolonging Drugs in Metastatic Castration-resistant Prostate Cancer: Results from the Dutch Castration-resistant Prostate Cancer Registry.

Kuppen MCP, Westgeest HM, van den Eertwegh AJM, van Moorselaar RJA, van Oort IM, Coenen JLLM, van den Bergh ACMF, Mehra N, Somford DM, Bergman AM, Ten Bokkel Huinink D, Fossion L, Geenen MM, Hendriks MP, van de Luijtgaarden ACM, Polee MB, Weijl NI, van de Wouw AJ, de Wit R, Uyl-de Groot CA, Gerritsen WR.

Eur Urol Oncol. 2019 Oct 7. pii: S2588-9311(19)30146-4. doi: 10.1016/j.euo.2019.09.005. [Epub ahead of print]

PMID:
31601523
5.

Implementation of a decision aid for localized prostate cancer in routine care: A successful implementation strategy.

van Tol-Geerdink JJ, van Oort IM, Somford DM, Wijburg CJ, Geboers A, van Uden-Kraan CF, de Vries M, Stalmeier PF.

Health Informatics J. 2019 Sep 30:1460458219873528. doi: 10.1177/1460458219873528. [Epub ahead of print]

PMID:
31566466
6.

68Ga-PSMA-PET/CT and Diffusion MRI Targeting for Cone-Beam CT-Guided Bone Biopsies of Castration-Resistant Prostate Cancer Patients.

van Steenbergen TRF, Smits M, Scheenen TWJ, van Oort IM, Nagarajah J, Rovers MM, Mehra N, Fütterer JJ.

Cardiovasc Intervent Radiol. 2019 Aug 23. doi: 10.1007/s00270-019-02312-8. [Epub ahead of print]

PMID:
31444628
7.

Second-Line Cabazitaxel Treatment in Castration-Resistant Prostate Cancer Clinical Trials Compared to Standard of Care in CAPRI: Observational Study in the Netherlands.

Westgeest HM, Kuppen MCP, van den Eertwegh AJM, de Wit R, Coenen JLLM, van den Berg HPP, Mehra N, van Oort IM, Fossion LMCL, Hendriks MP, Bloemendal HJ, van de Luijtgaarden ACM, Ten Bokkel Huinink D, van den Bergh ACMF, van den Bosch J, Polee MB, Weijl N, Bergman AM, Uyl-de Groot CA, Gerritsen WR.

Clin Genitourin Cancer. 2019 Oct;17(5):e946-e956. doi: 10.1016/j.clgc.2019.05.018. Epub 2019 May 31.

PMID:
31439536
8.

Introducing Decision Aids into Routine Prostate Cancer Care in The Netherlands: Implementation and Patient Evaluations from the Multi-regional JIPPA Initiative.

Cuypers M, Al-Itejawi HHM, van Uden-Kraan CF, Stalmeier PFM, Lamers RED, van Oort IM, Somford DM, van Moorselaar RJA, Verdonck-de Leeuw IM, van de Poll-Franse LV, van Tol-Geerdink JJ, de Vries M.

J Cancer Educ. 2019 Jul 5. doi: 10.1007/s13187-019-01572-9. [Epub ahead of print]

PMID:
31278659
9.

Patient Selection for Radium-223 Therapy in Patients With Bone Metastatic Castration-Resistant Prostate Cancer: New Recommendations and Future Perspectives.

van der Doelen MJ, Mehra N, Hermsen R, Janssen MJR, Gerritsen WR, van Oort IM.

Clin Genitourin Cancer. 2019 Apr;17(2):79-87. doi: 10.1016/j.clgc.2018.11.008. Epub 2018 Nov 22.

PMID:
30558834
10.

Immediate treatment vs. active-surveillance in very-low-risk prostate cancer: the role of patient-, tumour-, and hospital-related factors.

Jansen H, van Oort IM, van Andel G, Wijsman BP, Pos FJ, Hulshof MCCM, Hulsbergen-van de Kaa CA, van Leenders GJLH, Fütterer JJ, Somford DM, Busstra MB, van Moorselaar RJA, Kiemeney LA, Aben KKH.

Prostate Cancer Prostatic Dis. 2019 May;22(2):337-343. doi: 10.1038/s41391-018-0109-y. Epub 2018 Nov 14.

PMID:
30429595
11.

The Combination of Enzalutamide and Opioids: A Painful Pitfall?

Benoist GE, van Oort IM, Burger DM, Koch BCP, Mehra N, van Erp NP.

Eur Urol. 2019 Feb;75(2):351-352. doi: 10.1016/j.eururo.2018.09.011. Epub 2018 Sep 21. No abstract available.

PMID:
30245086
12.

Development and Validation of a Bioanalytical Method to Quantitate Enzalutamide and its Active Metabolite N-Desmethylenzalutamide in Human Plasma: Application to Clinical Management of Patients With Metastatic Castration-Resistant Prostate Cancer.

Benoist GE, van der Meulen E, van Oort IM, Beumer JH, Somford DM, Schalken JA, Burger DM, van Erp NP.

Ther Drug Monit. 2018 Apr;40(2):222-229. doi: 10.1097/FTD.0000000000000484.

13.

Value of Serial Multiparametric Magnetic Resonance Imaging and Magnetic Resonance Imaging-guided Biopsies in Men with Low-risk Prostate Cancer on Active Surveillance After 1 Yr Follow-up.

Hamoen EHJ, Hoeks CMA, Somford DM, van Oort IM, Vergunst H, Oddens JR, Smits GA, Bokhorst LP, Witjes JA, Rovers MM, Hulsbergen-van de Kaa CA, Barentsz JO.

Eur Urol Focus. 2019 May;5(3):407-415. doi: 10.1016/j.euf.2017.12.008. Epub 2018 Jan 10.

PMID:
29331622
14.

Epigenetic markers in circulating cell-free DNA as prognostic markers for survival of castration-resistant prostate cancer patients.

Hendriks RJ, Dijkstra S, Smit FP, Vandersmissen J, Van de Voorde H, Mulders PFA, van Oort IM, Van Criekinge W, Schalken JA.

Prostate. 2018 Apr;78(5):336-342. doi: 10.1002/pros.23477. Epub 2018 Jan 12.

15.

Difficulties in Pain Management Using Oxycodone and Fentanyl in Enzalutamide-Treated Patients With Advanced Prostate Cancer.

Westdorp H, Kuip EJM, van Oort IM, Kramers C, Gerritsen WR, Vissers KCP.

J Pain Symptom Manage. 2018 Apr;55(4):e6-e8. doi: 10.1016/j.jpainsymman.2017.11.016. Epub 2017 Nov 22. No abstract available.

PMID:
29175468
16.

223Ra Therapy in Patients With Advanced Castration-Resistant Prostate Cancer With Bone Metastases: Lessons from Daily Practice.

van der Doelen MJ, Kuppen MCP, Jonker MA, Mehra N, Janssen MJR, van Oort IM, Gerritsen WR.

Clin Nucl Med. 2018 Jan;43(1):9-16. doi: 10.1097/RLU.0000000000001904.

PMID:
29166331
17.

Drug-drug interaction potential in men treated with enzalutamide: Mind the gap.

Benoist GE, van Oort IM, Smeenk S, Javad A, Somford DM, Burger DM, Mehra N, van Erp NP.

Br J Clin Pharmacol. 2018 Jan;84(1):122-129. doi: 10.1111/bcp.13425. Epub 2017 Oct 18.

18.

A urinary biomarker-based risk score correlates with multiparametric MRI for prostate cancer detection.

Hendriks RJ, van der Leest MMG, Dijkstra S, Barentsz JO, Van Criekinge W, Hulsbergen-van de Kaa CA, Schalken JA, Mulders PFA, van Oort IM.

Prostate. 2017 Oct;77(14):1401-1407. doi: 10.1002/pros.23401. Epub 2017 Aug 29.

PMID:
28853167
19.

Cost-effectiveness of a new urinary biomarker-based risk score compared to standard of care in prostate cancer diagnostics - a decision analytical model.

Dijkstra S, Govers TM, Hendriks RJ, Schalken JA, Van Criekinge W, Van Neste L, Grutters JPC, Sedelaar JPM, van Oort IM.

BJU Int. 2017 Nov;120(5):659-665. doi: 10.1111/bju.13861. Epub 2017 Apr 29.

20.

Blood-based and urinary prostate cancer biomarkers: a review and comparison of novel biomarkers for detection and treatment decisions.

Hendriks RJ, van Oort IM, Schalken JA.

Prostate Cancer Prostatic Dis. 2017 Mar;20(1):12-19. doi: 10.1038/pcan.2016.59. Epub 2016 Dec 6. Review.

PMID:
27922627
21.

Pharmacokinetic Aspects of the Two Novel Oral Drugs Used for Metastatic Castration-Resistant Prostate Cancer: Abiraterone Acetate and Enzalutamide.

Benoist GE, Hendriks RJ, Mulders PF, Gerritsen WR, Somford DM, Schalken JA, van Oort IM, Burger DM, van Erp NP.

Clin Pharmacokinet. 2016 Nov;55(11):1369-1380. Review.

22.

Enzalutamide as a Fourth- or Fifth-Line Treatment Option for Metastatic Castration-Resistant Prostate Cancer.

Badrising SK, van der Noort V, Hamberg P, Coenen JL, Aarts MJ, van Oort IM, van den Eertwegh AJ, Los M, van den Berg HP, Gelderblom H, Vrijaldenhoven S, Kerver ED, van Voorthuizen T, de Jong IJ, Haanen JB, Bergman AM; Dutch Uro-Oncology Study Group (DUOS).

Oncology. 2016;91(5):267-273. Epub 2016 Aug 20.

PMID:
27544669
23.

Detection of High-grade Prostate Cancer Using a Urinary Molecular Biomarker-Based Risk Score.

Van Neste L, Hendriks RJ, Dijkstra S, Trooskens G, Cornel EB, Jannink SA, de Jong H, Hessels D, Smit FP, Melchers WJ, Leyten GH, de Reijke TM, Vergunst H, Kil P, Knipscheer BC, Hulsbergen-van de Kaa CA, Mulders PF, van Oort IM, Van Criekinge W, Schalken JA.

Eur Urol. 2016 Nov;70(5):740-748. doi: 10.1016/j.eururo.2016.04.012. Epub 2016 Apr 20.

PMID:
27108162
24.

The clinical phenotype of hereditary versus sporadic prostate cancer: HPC definition revisited.

Cremers RG, Aben KK, van Oort IM, Sedelaar JP, Vasen HF, Vermeulen SH, Kiemeney LA.

Prostate. 2016 Jul;76(10):897-904. doi: 10.1002/pros.23179. Epub 2016 Mar 14.

25.

Comparative analysis of prostate cancer specific biomarkers PCA3 and ERG in whole urine, urinary sediments and exosomes.

Hendriks RJ, Dijkstra S, Jannink SA, Steffens MG, van Oort IM, Mulders PF, Schalken JA.

Clin Chem Lab Med. 2016 Mar;54(3):483-92. doi: 10.1515/cclm-2015-0599.

PMID:
26630694
26.

PREDICT: model for prediction of survival in localized prostate cancer.

Kerkmeijer LG, Monninkhof EM, van Oort IM, van der Poel HG, de Meerleer G, van Vulpen M.

World J Urol. 2016 Jun;34(6):789-95. doi: 10.1007/s00345-015-1691-4. Epub 2015 Sep 29.

27.

Prognostic parameters for response to enzalutamide after docetaxel and abiraterone treatment in metastatic castration-resistant prostate cancer patients; a possible time relation.

Badrising SK, van der Noort V, van den Eertwegh AJ, Hamberg P, van Oort IM, van den Berg HP, Los M, Aarts MJ, Coenen JL, Gelderblom H, de Jong IJ, Kerver ED, Vrijaldenhoven S, van Voorthuizen T, Warmerdam F, Haanen JB, Bergman AM; Dutch Uro-Oncology Studygroup.

Prostate. 2016 Jan;76(1):32-40. doi: 10.1002/pros.23094. Epub 2015 Sep 22.

PMID:
26390914
28.

Systematic ultrasound-guided saturation and template biopsy of the prostate: indications and advantages of extended sampling.

Isbarn H, Briganti A, De Visschere PJ, Fütterer JJ, Ghadjar P, Giannarini G, Ost P, Ploussard G, Sooriakumaran P, Surcel CI, van Oort IM, Yossepowitch O, van den Bergh RC; Prostate Cancer Working Group of the European Association of Urology Young Academic Urologists.

Arch Esp Urol. 2015 Apr;68(3):296-306. Review.

PMID:
25948801
29.

Does a decision aid for prostate cancer affect different aspects of decisional regret, assessed with new regret scales? A randomized, controlled trial.

van Tol-Geerdink JJ, Leer JW, Wijburg CJ, van Oort IM, Vergunst H, van Lin EJ, Witjes JA, Stalmeier PF.

Health Expect. 2016 Apr;19(2):459-70. doi: 10.1111/hex.12369. Epub 2015 May 3.

30.

Identification of a Candidate Gene Panel for the Early Diagnosis of Prostate Cancer.

Leyten GH, Hessels D, Smit FP, Jannink SA, de Jong H, Melchers WJ, Cornel EB, de Reijke TM, Vergunst H, Kil P, Knipscheer BC, Hulsbergen-van de Kaa CA, Mulders PF, van Oort IM, Schalken JA.

Clin Cancer Res. 2015 Jul 1;21(13):3061-70. doi: 10.1158/1078-0432.CCR-14-3334. Epub 2015 Mar 18.

31.

Known susceptibility SNPs for sporadic prostate cancer show a similar association with "hereditary" prostate cancer.

Cremers RG, Galesloot TE, Aben KK, van Oort IM, Vasen HF, Vermeulen SH, Kiemeney LA.

Prostate. 2015 Apr 1;75(5):474-83. doi: 10.1002/pros.22933. Epub 2015 Jan 5.

32.

CAST: A retrospective analysis of cabazitaxel and abiraterone acetate sequential treatment in patients with metastatic castrate-resistant prostate cancer previously treated with docetaxel.

Wissing MD, Coenen JL, van den Berg P, Westgeest HM, van den Eertwegh AJ, van Oort IM, Bos MM, Bergman AM, Hamberg P, Ten Tije AJ, Los M, Lolkema MP, de Wit R, Gelderblom H.

Int J Cancer. 2015 Mar 15;136(6):E760-72. doi: 10.1002/ijc.29231. Epub 2014 Oct 3.

33.

Prognostic effect of neuroendocrine differentiation in prostate cancer: A critical review.

Surcel CI, van Oort IM, Sooriakumaran P, Briganti A, De Visschere PJ, Fütterer JJ, Ghadjar P, Isbarn H, Ost P, van den Bergh RC, Yossepowitch O, Giannarini G, Ploussard G; Members of the Prostate Cancer Working Group of the Young Academic Urologists Working Party of the European Association of Urology.

Urol Oncol. 2015 Jun;33(6):265.e1-7. doi: 10.1016/j.urolonc.2014.08.007. Epub 2014 Sep 17. Review.

PMID:
25238700
34.

Can we expand active surveillance criteria to include biopsy Gleason 3+4 prostate cancer? A multi-institutional study of 2,323 patients.

Ploussard G, Isbarn H, Briganti A, Sooriakumaran P, Surcel CI, Salomon L, Freschi M, Mirvald C, van der Poel HG, Jenkins A, Ost P, van Oort IM, Yossepowitch O, Giannarini G, van den Bergh RC; Members of the Prostate Cancer Working Group of the Young Academic Urologists Working Party of the European Association of Urology.

Urol Oncol. 2015 Feb;33(2):71.e1-9. doi: 10.1016/j.urolonc.2014.07.007. Epub 2014 Aug 15.

PMID:
25131660
35.

KLK3, PCA3, and TMPRSS2-ERG expression in the peripheral blood mononuclear cell fraction from castration-resistant prostate cancer patients and response to docetaxel treatment.

Dijkstra S, Leyten GH, Jannink SA, de Jong H, Mulders PF, van Oort IM, Schalken JA.

Prostate. 2014 Sep;74(12):1222-30. doi: 10.1002/pros.22839. Epub 2014 Jul 7.

PMID:
25043536
36.

Self-reported acne is not associated with prostate cancer.

Cremers RG, Aben KK, Vermeulen SH, den Heijer M, van Oort IM, van de Kerkhof PC, Schalken JA, Kiemeney LA.

Urol Oncol. 2014 Oct;32(7):941-5. doi: 10.1016/j.urolonc.2014.02.019. Epub 2014 Jul 8.

PMID:
25011577
37.

The oncologic role of local treatment in primary metastatic prostate cancer.

Ghadjar P, Briganti A, De Visschere PJ, Fütterer JJ, Giannarini G, Isbarn H, Ost P, Sooriakumaran P, Surcel CI, van den Bergh RC, van Oort IM, Yossepowitch O, Ploussard G.

World J Urol. 2015 Jun;33(6):755-61. doi: 10.1007/s00345-014-1347-9. Epub 2014 Jul 5. Review.

PMID:
24997127
38.

Preferences in the management of high-risk prostate cancer among urologists in Europe: results of a web-based survey.

Surcel CI, Sooriakumaran P, Briganti A, De Visschere PJ, Fütterer JJ, Ghadjar P, Isbarn H, Ost P, Ploussard G, van den Bergh RC, van Oort IM, Yossepowitch O, Sedelaar JP, Giannarini G; Members of Prostate Cancer Working Group of Young Academic Urologists Working Party; Members of Young Urologists Office of European Association of Urology.

BJU Int. 2015 Apr;115(4):571-9. doi: 10.1111/bju.12796. Epub 2014 Aug 11.

39.

Clinical activity and tolerability of enzalutamide (MDV3100) in patients with metastatic, castration-resistant prostate cancer who progress after docetaxel and abiraterone treatment.

Badrising S, van der Noort V, van Oort IM, van den Berg HP, Los M, Hamberg P, Coenen JL, van den Eertwegh AJ, de Jong IJ, Kerver ED, van Tinteren H, Bergman AM.

Cancer. 2014 Apr 1;120(7):968-75. doi: 10.1002/cncr.28518. Epub 2013 Dec 30.

40.

Value of 3-T multiparametric magnetic resonance imaging and magnetic resonance-guided biopsy for early risk restratification in active surveillance of low-risk prostate cancer: a prospective multicenter cohort study.

Hoeks CM, Somford DM, van Oort IM, Vergunst H, Oddens JR, Smits GA, Roobol MJ, Bul M, Hambrock T, Witjes JA, Fütterer JJ, Hulsbergen-van de Kaa CA, Barentsz JO.

Invest Radiol. 2014 Mar;49(3):165-72. doi: 10.1097/RLI.0000000000000008.

PMID:
24220253
41.

Prostate cancer biomarker profiles in urinary sediments and exosomes.

Dijkstra S, Birker IL, Smit FP, Leyten GH, de Reijke TM, van Oort IM, Mulders PF, Jannink SA, Schalken JA.

J Urol. 2014 Apr;191(4):1132-8. doi: 10.1016/j.juro.2013.11.001. Epub 2013 Nov 7.

PMID:
24211598
42.

Value of PCA3 to predict biopsy outcome and its potential role in selecting patients for multiparametric MRI.

Leyten GH, Wierenga EA, Sedelaar JP, van Oort IM, Futterer JJ, Barentsz JO, Schalken JA, Mulders PF.

Int J Mol Sci. 2013 May 28;14(6):11347-55. doi: 10.3390/ijms140611347.

43.

The predictive value of endorectal 3 Tesla multiparametric magnetic resonance imaging for extraprostatic extension in patients with low, intermediate and high risk prostate cancer.

Somford DM, Hamoen EH, Fütterer JJ, van Basten JP, Hulsbergen-van de Kaa CA, Vreuls W, van Oort IM, Vergunst H, Kiemeney LA, Barentsz JO, Witjes JA.

J Urol. 2013 Nov;190(5):1728-34. doi: 10.1016/j.juro.2013.05.021. Epub 2013 May 13.

PMID:
23680307
44.

Cabazitaxel in patients with metastatic castration-resistant prostate cancer: results of a compassionate use program in the Netherlands.

Wissing MD, van Oort IM, Gerritsen WR, van den Eertwegh AJ, Coenen JL, Bergman AM, Gelderblom H.

Clin Genitourin Cancer. 2013 Sep;11(3):238-250.e1. doi: 10.1016/j.clgc.2013.04.004. Epub 2013 May 6.

PMID:
23659772
45.

Quality of life after prostate cancer treatments in patients comparable at baseline.

van Tol-Geerdink JJ, Leer JW, van Oort IM, van Lin EJ, Weijerman PC, Vergunst H, Witjes JA, Stalmeier PF.

Br J Cancer. 2013 May 14;108(9):1784-9. doi: 10.1038/bjc.2013.181. Epub 2013 Apr 23.

46.

Evaluation of diffusion-weighted MR imaging at inclusion in an active surveillance protocol for low-risk prostate cancer.

Somford DM, Hoeks CM, Hulsbergen-van de Kaa CA, Hambrock T, Fütterer JJ, Witjes JA, Bangma CH, Vergunst H, Smits GA, Oddens JR, van Oort IM, Barentsz JO; MR-PRIAS Collaboration Group.

Invest Radiol. 2013 Mar;48(3):152-7. doi: 10.1097/RLI.0b013e31827b711e.

PMID:
23328910
47.

Prospective multicentre evaluation of PCA3 and TMPRSS2-ERG gene fusions as diagnostic and prognostic urinary biomarkers for prostate cancer.

Leyten GH, Hessels D, Jannink SA, Smit FP, de Jong H, Cornel EB, de Reijke TM, Vergunst H, Kil P, Knipscheer BC, van Oort IM, Mulders PF, Hulsbergen-van de Kaa CA, Schalken JA.

Eur Urol. 2014 Mar;65(3):534-42. doi: 10.1016/j.eururo.2012.11.014. Epub 2012 Nov 15.

PMID:
23201468
48.

A study based on whole-genome sequencing yields a rare variant at 8q24 associated with prostate cancer.

Gudmundsson J, Sulem P, Gudbjartsson DF, Masson G, Agnarsson BA, Benediktsdottir KR, Sigurdsson A, Magnusson OT, Gudjonsson SA, Magnusdottir DN, Johannsdottir H, Helgadottir HT, Stacey SN, Jonasdottir A, Olafsdottir SB, Thorleifsson G, Jonasson JG, Tryggvadottir L, Navarrete S, Fuertes F, Helfand BT, Hu Q, Csiki IE, Mates IN, Jinga V, Aben KK, van Oort IM, Vermeulen SH, Donovan JL, Hamdy FC, Ng CF, Chiu PK, Lau KM, Ng MC, Gulcher JR, Kong A, Catalona WJ, Mayordomo JI, Einarsson GV, Barkardottir RB, Jonsson E, Mates D, Neal DE, Kiemeney LA, Thorsteinsdottir U, Rafnar T, Stefansson K.

Nat Genet. 2012 Dec;44(12):1326-9. doi: 10.1038/ng.2437. Epub 2012 Oct 28.

49.

Choice between prostatectomy and radiotherapy when men are eligible for both: a randomized controlled trial of usual care vs decision aid.

van Tol-Geerdink JJ, Willem Leer J, Weijerman PC, van Oort IM, Vergunst H, van Lin EN, Alfred Witjes J, Stalmeier PF.

BJU Int. 2013 Apr;111(4):564-73. doi: 10.1111/j.1464-410X.2012.11402.x. Epub 2012 Aug 10.

50.

Initial experience with identifying high-grade prostate cancer using diffusion-weighted MR imaging (DWI) in patients with a Gleason score ≤ 3 + 3 = 6 upon schematic TRUS-guided biopsy: a radical prostatectomy correlated series.

Somford DM, Hambrock T, Hulsbergen-van de Kaa CA, Fütterer JJ, van Oort IM, van Basten JP, Karthaus HF, Witjes JA, Barentsz JO.

Invest Radiol. 2012 Mar;47(3):153-8. doi: 10.1097/RLI.0b013e31823ea1f0.

PMID:
22293513

Supplemental Content

Loading ...
Support Center